UBS and Morgan Stanley lowered their price targets for UiPath following its Q4 results. While the company met expectations, analysts cited limited near-term upside due to modest growth. UBS noted that constant-currency net new annual recurring revenue has not meaningfully expanded, signaling weak new business momentum.
Sponsored Advertisement
No comments yet. Be the first!